AGC Biologics Honored as a Top 10 Company for Pharma Quality Assurance
SEATTLE, June 09, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has been named a Top 10 Top Quality Assurance Services provider by Pharma Tech Outlook Europe.
The award, shared in the special Quality Assurance Edition (May 2022) of Pharma Tech Outlook Europe magazine, lists the top ten companies providing the best Quality Assurance services for the pharmaceutical industry. AGC Biologics is the only CDMO to be included in this year’s Top 10 Quality company list.
Pharma Tech Outlook is a leading global industry news source pioneering real-world solutions, news, product trends, and other important topics related to the pharmaceutical industry. The publication uses a collaborative, peer-driven approach to address the important needs of the industry. The magazine highlights leaders, innovative companies and important news impacting the pharmaceutical space.
“We are honored to accept the award as one of the Top 10 Quality Assurance Services Companies in our industry. As a company, we lead with quality and safety, and truly believe that quality is the responsibility of every individual at AGC Biologics,” said Paul Tsang, Executive Vice President of Global Quality, AGC Biologics. “I’m humbled to help guide the direction of our global team that cares deeply for our customers and their patients. This honor is a true testament to the hard work, dedication and work of everyone within the Global Quality organization.”
“Our integrated Quality Management System combined with our cGMP expertise helps us support our clients in not only performing in-process, intermediate, and final product testing, but also offering them faster time-to-market and improved success rates by building quality into products and processes,” notes Tina Guldberg, Vice President of Quality, AGC Biologics Copenhagen.
AGC Biologics offers an integrated quality management system (QMS), which incorporates requirements from the US, EU, Japan, and other major compliance and regulatory guidelines (e.g., ICH, PhEur, USP). The company’s facilities have been inspected by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada and the Pharmaceuticals and Medical Devices Agency (PMDA).
AGC Biologics is currently expanding at several facilities across the globe to grow quality and other important services, including at three sites in Europe in Copenhagen, Denmark, Heidelberg, Germany and Milan, Italy. These expansions support the company’s mission of furthering quality standards for pharmaceutical products it helps bring to market. In Copenhagen specifically, the company is building an additional facility that adds 8,000 square meters of space to the current mammalian and microbial biologics site. The new expansion includes state-of-the-art mammalian manufacturing capabilities, additional technical and warehouse space, and new quality control laboratories that will help the company continue to innovate its quality and regulatory services.
To learn more about AGC Biologics’ quality assurance, quality control and regulatory services, visit www.agcbio.com/capabilities/quality-regulatory.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Unveiling the 8th Future Investment Initiative’s theme: "Infinite Horizons: Investing Today, Shaping Tomorrow"17.4.2024 23:07:59 CEST | Press release
RIYADH, Saudi Arabia, April 18, 2024 (GLOBE NEWSWIRE) -- The Future Investment Initiative (FII) Institute is excited to announce the theme for its upcoming 8th edition of the FII conference, scheduled for October 29-31, 2024, at the prestigious King Abdulaziz International Conference Centre (KAICC) in Riyadh, Saudi Arabia. Under the captivating theme ‘Infinite Horizons: investing today, shaping tomorrow’, FII8 will ignite discussions on how investment can serve as a catalyst for a prosperous and sustainable future, pushing the boundaries of what is possible for humanity. FII8 promises to be a melting pot of innovative ideas, bringing together global leaders, entrepreneurs, political leaders, media and decision-makers in finance, AI, sustainability, energy, geoeconomics, space and beyond. By focusing on the theme of ‘Infinite Horizons’, this year’s conference will challenge attendees to think beyond conventional limits and explore investment opportunities that can bridge current challen
HMS Networks completes a placement of 3,500,000 shares, raising proceeds of SEK 1,400 million17.4.2024 22:45:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AND DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO PURCHASE THE SECURITIES DESCRIBED HEREIN, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. HMS Networks AB (publ) (“HMS” or the "Company") has, based on authorisation from the extraordinary general meeting on January 26, 2024, resolved to carry out a placement of 3,500,000 newly issued
HMS Networks har genomfört en riktad nyemission av 3 500 000 aktier och tillförs 1 400 miljoner SEK17.4.2024 22:45:00 CEST | Pressemelding
INTE AVSETT FÖR, OCH FÅR INTE, OFFENTLIGGÖRAS, PUBLICERAS ELLER DISTRIBUERAS, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, INOM ELLER TILL USA (INNEFATTANDE DESS TERRITORIER OCH BESITTNINGAR, VARJE STAT I USA SAMT DISTRICT OF COLUMBIA), AUSTRALIEN, KANADA, JAPAN, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION VORE OLAGLIG ELLER KRÄVA REGISTRERING ELLER ANDRA ÅTGÄRDER. DETTA PRESSMEDDELANDE UTGÖR INTE NÅGOT PROSPEKT OCH UTGÖR INTE NÅGOT ERBJUDANDE ATT SÄLJA ELLER FÖRVÄRVA DE VÄRDEPAPPER SOM BESKRIVS HÄRI, OCH DET SKA INTE SKE NÅGON FÖRSÄLJNING AV DE VÄRDEPAPPER SOM BESKRIVS HÄRI TILL ELLER INOM NÅGON JURISDIKTION DÄR SÅDANT ERBJUDANDE ELLER FÖRSÄLJNING VORE OLAGLIG FÖRE REGISTRERING ELLER KVALIFICERING ENLIGT VÄRDEPAPPERSREGLERNA I SÅDAN JURISDIKTION. HMS Networks AB (publ) (“HMS” eller "Bolaget") har, med stöd av bemyndigandet från den extra bolagsstämman den 26 januari 2024, beslutat att genomföra en riktad nyemission av 3 500 000 aktier til
Ingredion to Release 2024 First Quarter Financial Results on May 8, 202417.4.2024 22:05:00 CEST | Press release
WESTCHESTER, Ill., April 17, 2024 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food manufacturing industry, will release its 2024 first quarter financial results for the period ended March 31, 2024, before the market opens Wednesday, May 8, 2024. Jim Zallie, president and chief executive officer and Jim Gray, executive vice president and chief financial officer, will host a conference call May 8 at 8 a.m. CT to discuss the Company's financial performance. The conference call and accompanying slide presentation will be webcast live at https://ir.ingredionincorporated.com/events-and-presentations. Participants are encouraged to log on to the webcast approximately 10 minutes before the start of the presentation. A replay of the presentation will be available on the Company's website. ABOUT THE COMPANY Ingredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions pr
EMGS – Board of directors approves audited financial statements and annual report for 202317.4.2024 22:00:00 CEST | Press release
The board of directors of Electromagnetic Geoservices ASA ("EMGS" or the "Company") has today approved EMGS' 2023 annual financial statements and annual report. There are no material changes to the financial statements compared to the preliminary and unaudited full year results presented by the Company on 14 February 2024. EMGS' annual report for 2023 is enclosed to this stock exchange notification. The annual report will be published in European Single Electronic Format (ESEF) on or about Friday 19 April 2024. Contact Anders Eimstad, Chief Financial Officer, +47 948 25 836 This information is published in accordance with the Norwegian Securities Trading Act § 5-12. About EMGS EMGS, the marine EM market leader, uses its proprietary electromagnetic (EM) technology to support oil and gas companies in their search for offshore hydrocarbons. EMGS supports each stage in the workflow, from survey design and data acquisition to processing and interpretation. The Company's services enable the